IE910018A1 - Diphenylsulphoximine muscarinic receptor antagonists - Google Patents

Diphenylsulphoximine muscarinic receptor antagonists

Info

Publication number
IE910018A1
IE910018A1 IE001891A IE1891A IE910018A1 IE 910018 A1 IE910018 A1 IE 910018A1 IE 001891 A IE001891 A IE 001891A IE 1891 A IE1891 A IE 1891A IE 910018 A1 IE910018 A1 IE 910018A1
Authority
IE
Ireland
Prior art keywords
formula
alkyl
compound
spc
plc
Prior art date
Application number
IE001891A
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of IE910018A1 publication Critical patent/IE910018A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compounds of formula (I), wherein R and R<1> are H or C1-C4 alkyl; and X is a group of formulae (II) or (III), wherein either R<2> is H or C1-C4 alkyl and R<3> is C1-C4 alkyl, or R<2> and R<3> represent -(CH2)r- wherein r is from 2 to 5; R<4> is C1-C4 alkyl; X<1> is a direct link, O or S; R<5> is mono or disubstituted phenyl wherein the substituents are H, halo, C1-C4 alkyl, C1-C4 alkoxy, -(CH2)sOH, -(CH2)sNR<8>R<9>, -CONR<10>R<11>, -SO2NH2 or -OCO(C1-C4 alkyl), or adjacent substituents may form a fused ring; or R<5> is thienyl, pyridinyl or pyrazinyl; R<8> and R<9> are H or C1-C4 alkyl, or R<8> is hydrogen and R<9> is -SO2(C1-C4 alkyl), -CONR<10>R<11>, -CO(C1-C4 alkyl) or -SO2NH2; R<10> and R<11> are hydrogen or C1-C4 alkyl; m is 1, 2 or 3; n is 0, 1 or 2; p is 0 or 1; and s is 0, 1 or 2, (with certain provisos); are gastrointestinal and bladder selective muscarinic receptor antagonists of utility for example in irritable bowel syndrome.

Description

This invention relates to diphenylsulphoximine derivatives.
More specifically the invention relates to N-pyrrolidinyl(alkyl)/N-piperidinyl(alkyl)- and N-aminoalkylsubstituted diphenylsulphoximine derivatives which are gastrointestinal and bladder selective muscarinic receptor antagonists.
GB-A-1,168,700 discloses certain N-substituted aminoalkyl-S,S-diphenylsulphoximine derivatives which exhibit specific broncholytic-antispasmodic activity in mammals and which are useful in treating conditions generally associated with bronchial diseases.
The compounds of the present invention are useful for the curative or prophylactic treatment of disease states where the gastrointestinal and bladder selective reduction of acetylcholine-mediated smooth muscle contraction would be of 1 I benefit such as in the treatment of motility disorders of the gut, in particular as in irritable bowel syndrome, and in the treatment of urinary incontinence, emesis or diverticular disease.
Irritable bowel syndrome is a motility disorder characterised by altered bowel habit (i.e. constipation and/or diarrhoea), distension and abdominal pain. The muscarinic receptor antagonists of the present invention reduce the motility of the gut thus having an antispasmodic effect on the bowel without producing, or significantly reducing, bronchial or cardiac effects.
PLC 525 (SPC 7681) -' 2 Thus the present invention provides compounds of the formula :R R — (I) and pharmaceutically acceptable salts thereof, wherein R and are each independently H or C^-C^ alkyl; X is a group of the formula:and — CH„— C—N (CH„) Z . I Z TQ '3 4 R R or ) PLC 525 (SPC 7681) , IE 9118 wherein 3 either R is H or C^-C^ alkyl and R is C^-C^ alkyl, or 3 R and R taken together represent -(CH^ - wherein r is an integer of from 2 to 5; R is C^-C^ alkyl; χΐ is a direct link, 0 or S; R3 is a group of the formula:- or Het; either either R8 and R7 are each independently H, halo, C^-C^ alkyl, C.-C, alkoxy, -(CH.) OH, -(CH ) NR8R9, -CONR1°R11, Z S Z S -SO2NH2 or -OCO(C^-C4 alkyl), or R8 and R7 taken ' 2 3 together represent a group of the formula -X -(CH^^-X 2 3 wherein X and X are each independently 0 or CH2 and t is an integer of from 1 to 3; 9 8 R and R are each independently H or C^-C^ alkyl, or R is hydrogen and R9 is -SO2(C^-C4 alkyl), -CONR^r’’’, -CO(CL-C4 alkyl) or -SO2NH2; rIO and R^ are each independently hydrogen or C^-C^ alkyl; Het is thienyl, pyridinyl or pyrazinyl; m is 1, 2 or 3; n is 0, 1 or 2; p is 0 or 1; and PLC 525 (SPC 7681) s is 0, 1 or 2: with the provisos that (a) when m is 1, X^ is a direct link and is as defined above except for Het; and (b) when n is zero, the N-substituted pyrrolidinyl or piperidinyl ring is not attached via it's 2-position to the adjacent sulphoximine nitrogen atom.
In the above definitions halo means F, Cl, Br or I and and alkyl and alkoxy groups may be straight or branched chain.
For the above compounds of the formula (1):Preferably R and R^ are both H. 3 Preferably R is H or methyl and R is methyl; Preferably R is methyl Preferably X is a direct link.
Preferably is a group of the formula:PLC 525 (SPC 7681) 4K * r ? More preferably R is (C^-C^. alkoxy)phenyl, hydroxyphenyl or a group of the formula:- t wherein t is 1 or 2.
Most preferably R3 is 3- or 4-methoxyphenyl, 4-hydroxyphenyl, 3,4-methylenedioxyphenyl or 1,4-benzodioxan-6-yl.
Preferably m is 2.
Preferably n is 0 or 1.
When X contains a pyrrolidinyl or piperidinyl group, preferably X is either N-substituted-3-piperidinyl or i I N-substituted-2-pyrrolidinyImethyl, where the N-substituent is a group -(CH^^-X^-R3 as previously defined.
The pharmaceutically acceptable salts of the compounds of the formula (I) include acid addition salts formed from acids which form non-toxic salts such as the hydrochloride, hydrobromide, hydroiodide, sulphate or bisulphate, phosphate or hydrogen phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, mandelate, benzoate, salicylate, methanesulphonate, henzenesulphonate and para-toluenesulphonate salts.
PLC 525 (SPC 7681) The compounds of the formula (I) contain at least one asymmetric centre and will therefore exist as a pair of enantiomers or as diastereoisomeric pairs of enantiomers. Such enantiomers or diastereoisomeric pairs of enantiomers may be separated by physical methods, for example by fractional crystallisation, chromatography or H.P.L.C. of the racemic mixture of the parent compound, or of a suitable salt or derivative thereof. Alternatively an individual enantiomer or a particular diastereoisomeric pair of enantiomers may be prepared from a corresponding optically active intermediate.
The invention includes both the individual stereoisomers of the compounds of the formula (I) together with mixtures thereof.
A particularly preferred individual compound provided by the present invention is (3R)-N-[l-(4-methoxyphenethyl)piperidin-3yl]diphenylsulphoximine or a pharmaceutically acceptable salt thereof.
( I The compounds of the formula (I) provided by the invention may be prepared by the following methods, as illustrated in the following Examples section:PLC 525 (SPC 7681) 1) All the compounds of the formula (I) may be prepared as illustrated by Scheme 1:Scheme 1 1) Strong base,solvent R21 l 2) Y—CH — C— N-(CH„)X 2 *3 14 R R R' (HI) 1 Compounds (IV) 3 4 5 1 wherein R, R,R,R,R,R,m, n,p and X are as previously defined for the formula (I) and Y is a suitable leaving group, e.g. halo (preferably chloro or bromo), methanesulphonyloxy, trifluoromethanesulphonyloxy or p-toluenesulphonyloxy.
In a typical procedure, a diphenylsulphoximine derivative of the formula (II) is deprotonated with approximately one equivalent of a suitable strong base, e.g. sodium hydride, n-butyllithium or lithium diisopropylamide, and then reacted in situ with an alkylating agent of the formula (III) or (IV), as required, in a suitable inert organic solvent, e.g. xylene or toluene.
PLC 525 (SPC 7681) IE 9118 The reaction is preferably carried out by adding the strong base to a solution of compound (II) at about room temperature and under an inert atmosphere (e.g. of nitrogen or argon), then heating the resulting mixture at from 40°C to, and preferably at, the reflux temperature of the mixture for a short period to complete, or substantially complete, the deprotonation process.
The solution containing the anion of the diphenylsulphoximine derivative (II) is then cooled, treated with a solution of the alkylating agent and the reaction heated at from room temperature to, and preferably at, the reflux temperature of the mixture. The product of the formula (I) is isolated and purified by conventional techniques.
Although it is most convenient to deprotonate the diphenylsulphoximine derivative (II) in situ to provide the necessary anion, it is also possible to react the alkylating agent directly with a suitable salt of a compound of the formula (II), I e.g. the lithium, sodium, potassium or calcium salt.
The skilled man will appreciate that due to a competing rearrangement reaction the use of an alkylating agent (IV) of the formula:or N Y-H2C ' N 1 1 5 (CH ) -X -R m (V) (VI) PLC 525 (SPC 7681) IE 9118 wherein R , m, X and Y are as previously defined for a compound of the formula (IV), in this process may provide a mixture of products of the formula (I) wherein X is a group of the formula:or Ν' I 1 5 _(CH_) -X^-R3 Z m -CH N I i 5 (CH_) -X -RJ m (XA) (XB) wherein R, r\ R3, and m are as previously defined for the formula (I). Indeed in certain circumstances the rearrangement product may be the exclusive product of the reaction.
In many instances the attempted preparation of an alkylating agent of the formula (V) or (VI) results in a mixture of the required product together with the corresponding compound of the I I formula (VI) or (V), respectively. In certain circumstances the rearrangement product is the exclusive product of this intermediate preparation reaction.
Such (V)/(VI) mixtures may be used directly in this process and the corresponding mixture of products of the formula (I) obtained may be separated by conventional chromatographic techniques. ί PLC 525 (SPC 7681) This effect arises since a compound of the formula (V) or (VI) may readily form an aziridinium ion (VII) during preparation or, for example, under the conditions of the alkylation reaction (see the review article by M. Miocque and J. P. Duclos, Chimie Therapeutique, 1969 (5), 363-380, and references cited therein).
This aziridinium ion is open to two routes of nucleophilic attack by the anion derived from a diphenylsulphoximine derivative (II) in the alkylation reaction, thus accounting for the product mixture observed (Scheme 2).
Scheme 2 Compounds (V) Compounds (VI) (VII) Compounds (I) wherein X is a group of the formula (XA) or (XB) where Nu represents the nucleophilic anion derived by deprotonation of a compound of the formula (II).
PLC 525 (SPC 7681) IE 9118 2) All the compounds of the formula (I) may be prepared as illustrated by Scheme 3:- Acid acceptor,solvent -Compounds (I) 3 4 5 1 wherein R,R,R,R,R,R,m,n,p and X are as previously defined for the formula (I) and Y^ is a suitable leaving group, e.g. halo (preferably chloro, bromo or iodo), methanesulphonyloxy, trifluoromethanesulphonyloxy or p-toluenesulphonyloxy.
In a typical procedure a compound of the formula (VIII) or (IX) , as appropriate, is reacted with a compound of the formula (X) in the presence of a suitable acid acceptor, e.g. sodium or PLC 525 (SPC 7681) IE 9118 potassium carbonate, and, where is chloro or bromo, optionally in the presence of sodium or potassium iodide to accelerate the rate of the reaction. The reaction is carried out in a suitable organic solvent, e.g. acetonitrile, at from room temperature to, and preferably at, the reflux temperature of the mixture. The product of the formula (I) is then isolated and purified by conventional techniques. 3) A compound of the formula:- I 1 CH2CH2-Het (XII) PLC 525 (SPC 7681) 3 4 wherein R, R , R , R , R , n and p are as previously defined for the formula (I) and Het^” is 2- or 4-pyridinyl or pyrazinyl, may be conveniently prepared by a Michael-type addition reaction by reacting a compound of the formula (VIII) or (IX), respectively, 12 3 4 wherein R, R , R , R , R , n and p are as previously defined for the formula (I), with a compound of the formula Het3-CH=CH2, wherein Het^ is as previously defined in this method. The I reaction may be carried out using at least one equivalent, and preferably an excess, of the vinylheterocycle of the formula Het^CH=CH2 and optionally in the presence of a suitable organic solvent, e.g. 1,4-dioxane. The rate may be accelerated by elevating the reaction temperature and/or by the addition of a suitable acidic or basic catalyst, e.g. benzyltrimethylammonium hydroxide. The product of the formula (XI) or (XII) may be isolated and purified by conventional techniques.
I 4) A compound of the formula (I) wherein X is a group of the formula:- PLC 525 (SPC 7681) wherein R, R , X , m and p are as defined for the formula (I) and 5 R is as defined for the formula (I) with the exception that when neither R6 nor R7 can be -CONR^r’’’’, -(CH^)sNHCO(C^-C4 alkyl), -(CH.) NHCONR1°R11, -(CH.) NHSO.(C..-C. alkyl) or -OCO(C,-C, Z S Z S Ζ X 4 14 alkyl), wherein R^, r’-’- and s are as defined for the formula (I), may be prepared by reduction of a compound of the formula:- wherein R, R , R , X , m and p are as previously defined in this method, using a suitable strong reducing agent, e.g. aluminium hydride, and in a suitable inert organic solvent, e.g. tetrahydrofuran.
The reaction is typically carried out by generating aluminium hydride in situ by treating an ice-cooled suspension of lithium aluminium hydride in tetrahydrofuran with concentrated sulphuric PLC 525 (SPC 7681) acid. Compound (XIII) is then added and the resulting mixture is stirred at from 0°C to the reflux temperature of the mixture, preferably at about room temperature. The product of the formula (I) is isolated and purified by conventional techniques.
) Some of the compounds of the formula (I) wherein R is a substituted phenyl group may be prepared from other compounds of [ the formula (I) as follows:a) A C^-C^ alkoxy, preferably methoxy, substituent on the phenyl group may be converted to hydroxy by treatment with hydrogen bromide. Preferably aqueous hydrobromic acid is used at from room temperature to, and preferably at, the reflux temperature of the mixture.
This dealkylation can also be achieved by treatment with either a C^-C^ alkanethiol in the presence of a strong base, i e.g. sodium hydride, or directly with a suitable C^-C^ alkanethiolate salt, e.g. the sodium salt, and in a suitable organic solvent. The reaction may be heated to accelerate the rate. Butanethiol is the preferred thiol. b) A -CONrIOrU substituent on the phenyl group, wherein ρΐθ and are as previously defined for the formula (1), may be reduced to -CH^NR^Or^ with a suitable reducing agent, e.g. diborane. The reaction is typically carried out in a suitable organic solvent, e.g. tetrahydrofuran, at from room temperature to the reflux temperature of the mixture.
PLC 525 (SPC 7681) c) A hydroxy substituent on the phenyl group may be converted to -OCO(C^-C4 alkyl) by acylation using either a C^-C^ alkanoyl chloride or bromide, or a C^-C^ alkanoic anhydride. The presence of an acid acceptor is preferable, e.g. sodium bicarbonate or pyridine. The reaction is typically carried out in a suitable organic solvent at from 0°C to room temperature and heating is not usually necessary.
If an acid chloride is used the reaction may be carried out in pyridine, the pyridine acting as both the solvent and the acid acceptor.
If an acid anhydride is used the reaction may be carried out in the presence of an excess of the acid anhydride and in the absence of additional solvent or an acid acceptor. d) A -(CH2)sNH2 substituent on the phenyl group, wherein s is 0, 1 or 2, may be converted to -(CHpsNHC0(C^-C4 alkyl) by I acylation with a C^-C^ alkanoyl chloride or bromide or a C^-C^ alkanoic anhydride. The reaction may be carried out similarly to method 5(c) above. e) A -(CH2)sNH2 substituent on the phenyl group, wherein s Is 0, 1 or 2, may be converted to -(CH„) NHS0„(C.,-C, alkyl) by reaction with either a C^-C^ alkanesulphonyl chloride or bromide, or a C^-C^ alkanesulphonic anhydride and in a suitable organic solvent. The presence of an acid acceptor, PLC 525 (SPC 7681) IE 9118 such as pyridine, sodium bicarbonate or sodium or potassium carbonate, is preferable. When a sulphonyl chloride is used the reaction is most conveniently carried out in pyridine, the pyridine functioning as both the solvent and the acid acceptor. The reaction usually proceeds at from 0°C to room temperature and heating is not necessary. f) A -(CH2)sNH2 substituent on the phenyl group, wherein s is 0, 1 or 2, may be converted to -(Cl^) NHSt^N^ by reaction with sulphamide. The reaction is typically carried out at the reflux temperature in a suitable organic solvent, e.g. 1,4-dioxane. g) A hydroxy substituent on the phenyl group may be converted to C^-C^ alkoxy, firstly by reaction with a suitable strong base, such as sodium hydride, and then by I I reaction with a C^-C^ alkyl bromide or iodide. The reaction is preferably carried out at about room temperature in a suitable solvent, e.g. Ν,Ν-dimethylformamide. h) A -(CH2)sNH2 substituent on the phenyl group, wherein s is 0, 1 or 2, may be converted to -(CH„) NHCONH(C -C, alkyl) Z s 14 by reaction with a C^-C^ alkyl isocyanate. The reaction is typically carried out at about room temperature in a suitable organic solvent, e.g. dichloromethane.
» * IE 9118 Γ,τ^ rn5 (gpC 76gl) i) A -(CH2)sNHCO(C],-C4 alkyl) substituent on the phenyl group, wherein s is 0, 1 or 2, may be hydrolysed to -(CH2)sNH2 under aqueous conditions using a suitable strong acid (e.g. hydrochloric acid) or base (e.g. sodium or potassium hydroxide). The reaction is usually heated to accelerate the rate. j) A -CH20H substituent on the phenyl group may be 9 8 9 converted to -CH^NR R , wherein R and R are each independently H or C^-C^ alkyl, by reaction firstly with a suitable halogenating agent, e.g. thionyl chloride, and 8 9 secondly with ammonia or the required amine R R NH. The reaction with thionyl chloride is typically carried out with heating, preferably under reflux, and optionally in a suitable organic solvent, e.g. dichloromethane. The reaction with ammonia or the amine is typically carried out in a i I > suitable organic solvent, e.g. ethanol, at from room temperature to the reflux temperature of the solvent: most conveniently a bomb is used as the reaction vessel.
The intermediates used in the preparation of the compounds of the formula (I) provided by the invention may be prepared by the following methods, as illustrated in the following Preparations section:PLC 525 (SPC 7681) 1) The diphenylsulphoximine derivatives of the formula (II) may be prepared by the routes, or similar routes, to those disclosed in the literature references a) F. Misani, T. W. Fair, L. Reiner, J.A.C.S., 73, 459 (1951); and b) G. Satzinger, P. Stoss, Arz. Forsch., 20, 1214 (1970).
I An alternative method of preparation is disclosed in Preparation 26.
PLC 525 (SPC 7681) IE 9118 2) The intermediates of the formula (III) may be prepared as illustrated in Scheme 4:Scheme 4 HO-CH2-C-NH2 -- 13 R (XIV) Reductive Amination HO-CH.-C-NHR i3 R (XV) Y1-(CHO) -X^R5, Z El (X) Acid acceptor Y1-(CH_) -X^R5, Z El (X) Acid acceptor -L i3 HO-CH2-t-NH -(01,,)^¼5 (wherein 1 1 5 HO-CH.-C — N-(CH-) -X -R 2 I I 2 m '3 *4 R R R = methyl) (XVI) (XVII) Y-CH.-C—N-(CH.) -XL-R52 ι i 2 m 4 R R (HI) 4/ PLC 525 (SPC 7681) 3 4 5 1 wherein R , R , R , R , m, X and Y are as previously defined for the formula (III) and Y^ is as previously defined for the formula (X).
In a typical procedure an aminoalcohol of the formula (XIV) or (XV) is alkylated with a compound of the formula (X) in the presence of a suitable acid acceptor, e.g. sodium or potassium carbonate, and in a suitable organic solvent, e.g. acetonitrile. The reaction is preferably heated under reflux and, when Y^ is chloro or bromo, the reaction is optionally carried out in the presence of sodium or potassium iodide, in order to accelerate the rate of reaction.
The secondary amine of the formula (XVI) may be methylated to 4 provide the tertiary amine (XVII), wherein R is methyl, using conventional procedures. The methylation may be carried out by reacting (XVI) with either an aqueous solution of formaldehyde in formic acid under reflux conditions, or by reacting (XVI) with a I I solution of formaldehyde in methanol in the presence of sodium cyanoborohydride.
The alcohol of the formula (XVII) may be converted to a compound of the formula (III) by conventional techniques, e.g. when Y represents chloro or bromo, by reaction with thionyl chloride or bromide respectively; most preferably, when Y is chloro, a compound (III) is formed by reaction with methanesulphonyl chloride in dichloromethane in the presence of triethylamine.
The intermediates of the formula (XIV), (XV), (XVI) and (XVII) used in the preparation of compounds of the formula (III) may be advantageously used in this process with a protected hydroxy group. Suitable protecting groups for this purpose may PLC 594 (spc 7681) include those listed in Protective Groups in Organic Synthesis, Theodora W. Greene (John Wiley & Sons). Triphenylmethyl is the preferred protecting group. A protected compound (XVII) may then be deprotected by a conventional procedure prior to conversion to compound (III), e.g. when the hydroxy group is protected with triphenylmethyl the protecting group may be removed by refluxing in aqueous acetic acid. 3) The intermediates of the formula (IV) may be prepared as illustrated in Scheme 5:Scheme 5 (XVIII) n • 1 5 (CH„) -X -R Z m (XIX) (IV) PLC 525 (SPC 7681) IE 9118 1 wherein R , m, η, ρ, X and Y are as previously defined for the formula (I) and Y^ is as previously defined for the formula (X).
Compounds of the formula (XVIII), which are either commercially available or prepared by conventional literature procedures, may be alkylated using a compound (X) in the presence of an acid acceptor by a similar method to that previously described for the alkylation of compounds (XIV) and (XV) (see intermediate preparative method (2) above).
A compound of the formula (XIX) may he converted to a compound (IV) by conventional procedures. Y is preferably chloro and such compounds are prepared by reaction of compound (XIX) with either methanesulphonyl chloride or thionyl chloride, the reaction being carried out in a suitable organic solvent, e.g. dichloromethane, in the presence of an acid acceptor, e.g. triethylamine or pyridine, or with thionyl chloride in chloroform.
As previously discussed in method (1) for the preparation of I I compounds of the formula (I) above, an attempt to prepare an . intermediate (V) or (VI) may result in a product mixture of (V) and (VI) being obtained due to aziridinium ion (VII) formation under the preparative conditions used. Indeed in certain circumstances the rearrangement product may be the exclusive product of the reaction. Such (V/VI) product mixtures, when formed, are usually used directly in the synthesis of compounds of the formula (I) without further purification. 4) The intermediates of the formula (VIII) and (IX) may be prepared as illustrated in Scheme 6:PLC 525 (SPC 7681) 9118 ----' 24 Scheme 6 N-Z or Compounds (VIII) or (IX) 3 4 wherein R , R , R , R , n and p are as previously defined for the 2 formula (I), Y is a suitable leaving group, e.g. p-toluenesulphonyloxy, and Z is a suitable protecting group, e.g. p-toluenesulphonyl or benzyloxycarbonyl.
Compound (II) is alkylated with either a compound (XX) or (XXI), as appropriate, by a similar method to that disclosed in method (1) for the preparation of compounds of the formula (I) above, where an alkylating agent of the formula (III) or (IV) is used instead.
The resulting product, (XXII) or (XXIII), may be deprotected under conventional conditions, e.g. when Z is p-toluenesulphonyl· using sodium bis(2-methoxyethoxy)aluminium hydride (Red-Al®) in toluene, to provide a compound of the formula (VIII) or (IX), respectively.
PLC 525 (SPC 7681) ) The alkylating agents of the formula (X) and the vinylheterocycles of the formula Het^CH^^ are either known compounds which may be commercially available, or are prepared by conventional procedures in accordance with literature precedents. 6) The intermediates of the formula (XIII) may be prepared as illustrated in Scheme 7:Scheme 7 CO(Cl or OH) CH, Y (XXIV) + H N-(CH„) -X1—R.5 2 2 m (XXV) (CH, CONH-(CH-) -xZr5 2 m Y (XXVI) j.
D-·'· (XXVII) NI 1 5 (CH ) -XX-R3 m R Strong base (II) Compounds (XIII) ητ /» (SPC 7681) wherein R, r\ R3, x\ m and p are as defined for the formula (I) 4 and Y and Y , which may be the same or different, are suitable leaving groups, e.g. halo (preferably chloro or bromo). Most 3 4 preferably Y and Y are both bromo.
A compound of the formula (XXVI) may be prepared from an amine of the formula (XXV) either by acylation with an acid chloride of the formula (XXIV, Cl) in a suitable solvent, e.g. toluene, and in the presence of a suitable acid acceptor, e.g. pyridine or triethylamine, or hy reacting with a carboxylic acid of the formula (XXIV, OH) under conventional peptide coupling conditions.
An amide (XXVI) may be cyclised to a lactam (XXVII) under 3 4 standard conditions, for example where Y and Y are both bromo by stirring the amide (XXVI) with Amberlite® IRA-400 (Cl) ion exchange resin, dichloromethane and aqueous sodium hydroxide solution at about room temperature.
I A lactam (XXVII) may be then reacted with an anion formed ι from a diphenylsulphoximine derivative (II) to provide a compound (XIII) using a similar alkylation method to that described in method (1) for the preparation of compounds of the formula (I) above.
The starting materials of the formulae (XXIV) and (XXV) are either known compounds which may be commercially available or are prepared by conventional procedures in accordance with literature precedents.
PLC 525 (SPC 7681) -__ 27 Pharmaceutically acceptable acid addition salts are readily prepared by mixing solutions containing equimolar amounts of the free base and the desired acid. The salt generally precipitates from solution and is collected by filtration, or is recovered by evaporation of the solvent.
The selectivity of the compounds as muscarinic receptor antagonists can be measured as follows.
I Male guinea pigs are sacrificed and the ileum, trachea, bladder and right atrium are removed and suspended in physiological salt solution under a resting tension of 1 g at 32°C and aerated with 95% and 5% CC^. Contractions of the ileum, bladder and trachea are recorded using an isotonic (ileum) or isometric transducer (bladder and trachea). The frequency of contraction of the spontaneously beating right atrium is derived from isometrically recorded contractions.
Dose-response curves to either acetylcholine (ileum) or I I carhachol (trachea, bladder and right atrium) are determined using a 1-5 minute contact time for each dose of agonist until the maximum response is achieved. The organ bath is drained and refilled with physiological salt solution containing the lowest dose of the test compound. The test compound is allowed to equilibrate with the tissue for 20 minutes and the agonist dose-response curve is repeated until the maximum response is obtained. The organ bath is drained and refilled with physiological salt solution containing the second concentration of test compound and the above procedure is repeated. Typically four concentrations of the test compound are evaluated on each tissue.
PLC 525 (SPC 7681) The concentration of the test compound which causes a doubling of the agonist concentration required to produce the original response is determined (pA2 value - Arunlakshana and Schild, Brit. J. Pharmacol., 1959, 14, 48-58). Using the above analytical techniques, tissue selectivity for muscarinic receptor antagonists is determined.
Activity against agonist induced gut or bladder contractility in comparison with changes in heart rate is determined in the anaesthetised dog. Oral activity is assessed in the conscious dog determining compound effects on, for example, heart rate, pupil diameter and gut motility.
Compound affinity for other cholinergic sites is assessed in the mouse after either intravenous or intraperitoneal administration. Thus, the dose to cause a doubling of pupil size is determined as well as the dose to inhibit by 50% the salivation and tremor responses to intravenous oxotremorine. i For administration to man in the curative or prophylactic treatment of diseases where the gastrointestinal and bladder selective reduction of acetylcholine-mediated smooth muscle contraction would be of benefit such as in the treatment of motility disorders of the gut, in particular as in irritable bowel syndrome, and in the treatment of emesis, diverticular disease or urinary incontinence, oral dosages of the compounds will generally be in the range of from 3.5 to 350 mg daily for an average adult patient (70 kg). Thus for a typical adult patient, individual tablets or capsules will typically contain from 1 to 250 mg of active compound in a suitable pharmaceutically acceptable vehicle PLC 5?5 (SPC 7681) or carrier for administration singly or in multiple doses, once or several times a day. Dosages for intravenous administration will typically be within the range 0.35 to 35 mg per single dose as required. In practice the physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case but there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
For human use, the compounds of the formula (I) can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, they may be administered orally in the form of tablets containing such excipients as starch or lactose, I I ’ or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. They may be injected parenterally, for example, intravenously, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.
Thus, in a further aspect, the invention provides a pharmaceutical composition comprising a compound of the formula (I), or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.
PLC 525 (SPC 7681) The invention also includes a compound of the formula (I) or a pharmaceutically acceptable salt or composition thereof, for use as a medicament, particularly for use in the treatment of irritable bowel syndrome.
The invention further includes the use of a compound of the formula (I), or of a pharmaceutically acceptable salt or composition thereof, for the manufacture of a medicament for the treatment of diseases associated with motility disorders of the gut such as irritable bowel syndrome, and for the treatment of emesis, diverticular disease and urinary incontinence.
The invention yet further provides a method of treating a human being to cure or prevent either a disease associated with a motility disorder of the gut, such as irritable bowel syndrome, or emesis, diverticular disease or urinary incontinence, which comprises treating said human being with an effective amount of a compound of the formula (I), or with, as appropriate, a i pharmaceutically acceptable salt or composition thereof.
The invention also includes any novel intermediates disclosed herein, such as those of the formulae (VIII), (IX) and (XIII).
The following Examples illustrate the invention: PLC 525 (SPC 7681) IE 9118 ----------31 EXAMPLES IA and IB (3R)-N-[l-(4-Methoxyphenethyl)piperidin-3-yl]diphenylsulphoximine (Example IA) and (2S)-N-[(l-[4-methoxyphenethyl]pyrrolidin-2yl)methyl]diphenylsulphoximine (Example IB) Sodium hydride (80% dispersion in oil, 0.42 g) was added to a solution of diphenylsulphoximine (2.39 g) in xylene (50 ml). The mixture was heated under reflux for 15 minutes, cooled, and treated with a solution of (3R)-chloro-l-(4-methoxyphenethyl)piperidine (2.50 g) (see Preparation 1) in xylene (25 ml). The resulting mixture was heated under reflux for 17 hours. The reaction was cooled, diluted with ethyl acetate and water and the layers were separated. The organic layer was dried (magnesium sulphate) and concentrated in vacuo.
PLC 525 (SPC 7681) Column chromatography on silica gel using ethyl acetate as the eluant provided two distinct products.
The fractions containing the less polar material were combined and concentrated in vacuo to provide the title compound (Example IA) as a pale yellow oil (0.45 g, 10%), [csz.]^gg +69.5° (c = 1.0 in ethanol). Found: C,71.5; H,7.0; N,6.3; Co.Hor,N„0„S zb 30 z z requires: C,71.7; H,7.2; N,6.4%.
The fractions containing the more polar material were combined and concentrated in vacuo to provide the title compound (Example IB) as a pale yellow oil (1.50 g, 34%), [O4.]||g -80.5° (c = 1.0 in ethanol). Found: C,71.3; H»6.7; N,6.1; ^26Η3θΝ2θ28 requires: C,71.7; H,7.2; N,6.4%.
EXAMPLES 2A, 2B, 3A, 3B, 4A, 4B„ 5A and 5B The following tabulated Examples are for compounds of the general formula:I I The Examples were each prepared by a similar method to that described for Examples IA and IB by reacting diphenylsulphoximine with sodium hydride in refluxing xylene and then treating the mixture with the appropriate alkylating agent, followed by work-up and separation of the required product.
PLC 525 (SPC 7681) E9118 ---' 33 The starting material used in the preparation of Examples 4A and 4B was obtained as described in Preparation 4 as the hydrochloride salt. This was converted to the corresponding free base for use in the reaction by basifying with 2M aqueous sodium hydroxide solution, extracting the aqueous mixture with diethyl ether, drying the organic extract over sodium sulphate followed by concentration thereof in vacuo to provide the required material. ΙΕ 9118 X txj IE 9118 PLC 525 (SPC 7681) 9118 -- ' 38 EXAMPLE 6 N-[l-(4-Methoxyphenethyl)piperidin-3-yl]diphenylsulphoximine A solution of concentrated sulphuric acid (82 mg) in tetrahydrofuran (2 ml) was added dropwise over 15 minutes to a stirred, ice-cooled suspension of lithium aluminium hydride (64 mg) in tetrahydrofuran (2 ml). The mixture was stirred with ice-cooling for one hour, treated with a solution of N-[l-(4I I » methoxyphenethyl)-2-oxopiperidin-3-yl]diphenylsulphoximine (0.37 g) (see Preparation 11) in tetrahydrofuran (6 ml) and then further stirred at room temperature for 4 hours. The mixture was quenched by the dropwise addition of saturated aqueous ammonium chloride solution and filtered. The filtrate was evaporated in vacuo. The residue was purified by chromatography on silica gel, performing a gradient elution using 0-2% methanol/dichloromethane as the eluant. The appropriate fractions were combined and evaporated in vacuo to give the title compound as a colourless solid (117 mg, 33%), m.p. 133-135°C, which was characterised by ^H-NMR spectroscopy.
PLC 525 (SPC 7681) ’'H-NMR (CDClg) & = 8.00 (dd, J = 8 and 2Hz, 4H), 7.43-7.59 (m, 6H), 7.14 (d, J = 8Hz, 2H) , 6.82 (d, J = 8Hz, 2H), 3.81 (s, 3H), 3.13-3.31 (m, 2H), 2.55-2.90 (m, 5H), 2.19 (t, J = 7Hz, IH) , 1.4-2.1 (m, 5H) ppm.
EXAMPLE 7 (3R)-N-[l-(4-Hydroxyphenethyl)piperidin-3-yl]diphenylsulphoximine I A solution of (3R)-N-[l-(4-methoxyphenethyl)piperidin-3yl]diphenylsulphoximine (0.20 g) (see Example IA) in 48% aqueous hydrobromic acid (8 ml) was heated under reflux for 1.5 hours then cooled and evaporated in vacuo. The residue was basified with saturated aqueous sodium hydrogen carbonate solution and extracted with dichloromethane. The combined organic extracts were washed with water, dried over sodium sulphate and evaporated in vacuo to give the title compound as a pale brown solid (60 mg, 31%), m.p. 115-118°C, +^θ·8° (c = 1.0 in methanol). Found: C,69.8; H,6.4; N,6.7; £25Η28Ν2θ2$.0.5 F^O requires: C,69.9; H,6.8; N,6.5%.
PLC 525 (SPC 7681) ~ ' 40 EXAMPLE 8 N-[2-(N,-[4-Methoxyphenethyl]-Nl-methyl)amino-2-methylprop-lyl]diphenylsulphoximine Sodium hydride (80% dispersion in oil, 33 mg) was added to a solution of diphenylsulphoximine (217 mg) in toluene (15 ml) and i the mixture was heated under reflux for 15 minutes, cooled and treated with a solution of l-chloro-2-(N-[4-methoxyphenethyl]N-methyl)amino-2-methylpropane (256 mg) (see Preparation 18) in toluene (5 ml). The mixture was heated under reflux for 8 hours, allowed to cool to room temperature and diluted with ethyl acetate and water. The layers were separated and the organic layer was washed with water, dried over sodium sulphate and evaporated in vacuo. The residue was purified by chromatography on silica gel performing a gradient elution using 0-5% methanol/dichloromethane as the eluant. The appropriate fractions were combined and evaporated in vacuo to give the title compound (85 mg, 19%) as a colourless foam. Found: C,71.2; H,7.5; N,6.4; C„.HooN„0„S Zb 3Z Z Z requires: C.71.5; H,7.4; N,6.4%.
PLC 52S (SPC 7681) IE 9118 EXAMPLE 9 N-[(2S)-[Ν'-(4-Methoxyphenethyl)-N'-methyl]aminoprop-1yl]diphenylsulphoximine The title compound of the formula:- och3 was prepared by a similar method to that used in Example 8 using l-chloro-2(S)-(N-[4-methoxyphenethyl]-N-methyl)aminopropane (see Preparation 21) instead of l-chloro-2-(N-[4-methoxyphenethyl]N-methyl)amino-2-methylpropane as the starting material. The title compound was obtained as an oil. Found: C.70.45; H,7.4; I I N,6.5;:C25H N202S.0.25 H20 requires: C.70.3; H,7.2; N,6.6%.
The following Preparations illustrate the preparation of starting materials used in the preceding Examples:PLC 525 (SPC 7681) Preparation 1 (3R)-Chloro-l-(4-methoxyphenethyl)piperidine A mixture of methanesulphonyl chloride (1.3 ml), triethylamine (1.7 g) and (2S)-[l-(4-methoxyphenethyl)]pyrrolidinemethanol (4.0 g) (see Preparation 6) in dichloromethane (30 ml) was stirred at room temperature for 2.5 hours, diluted with dichloromethane, washed with 10% aqueous sodium carbonate solution, dried over sodium sulphate and evaporated under reduced pressure to give the title compound as a pale brown oil (4.0 g) * ' 1 which was characterised by H-NMR spectroscopy and used directly in the preparation of Examples IA and IB without further purification. 1H-NMR (300 MHz, CDCip = 7.17 (d, 2H, J = 8Hz) , 6.84 (d, 2H, J = 8Hz), 4.01-4.13 (m, 1H), 3.82 (s, 3H), 3.19 (d, 1H, J = 14 Hz), 2.58-2.84 (m, 5H), 2.32 (t, 1H, J = 14 Hz), 1.6-2.3 (m, 4H) ppm.
PLC 575 /SPC 7681) IE 9118 Preparation 2 (3R)-Chloro-1-(3,4-methylenedioxyphenethyl)piperidine and (2S)-chloromethy1-1-(3,4-methylenedioxyphenethyl)pyrrolidine Thionyl chloride (4 ml) was added cautiously to a mixture of (2S)-[l-(3,4-methylenedioxyphenethyl)]pyrrolidinemethanol (5.0 g) I I (see Preparation 7) and pyridine (0.2 ml) in dichloromethane (70 ml). The resulting mixture was heated under reflux for 3 hours then cooled and evaporated in vacuo. The residue was triturated with diethyl ether and the resulting solid was collected by filtration, dissolved in water, basified with saturated aqueous sodium hydrogen carbonate solution and extracted with dichlorome thane.
The combined organic extracts were dried over sodium sulphate and evaporated in vacuo to give a pale brown oil (2.7 g, 51%), which was shown by ’'H-NMR spectroscopy to consist of a mixture of the two title compounds. This mixture was used directly in the preparation of Examples 2A and 2B without further purification.
PLC 525 (SPC 7681) Preparation 3 (3R)-Chloro-1-[2-(1,4-benzodioxan-6-y1)ethyl]piperidine and (2S)-chloromethyl-1-[2-(benzodioxan-6-yl)ethyl]pyrrolidine Thionyl chloride (0.8 ml) was added cautiously to a mixture of (2S) — (1—[2-(1,4-benzodioxan-6-yl)ethyl])pyrrolidinemethanol I I (1.0 g) (see Preparation 8) and pyridine (0.10 g) in dichloromethane (20 ml). The mixture was heated under reflux for hours then cooled and evaporated in vacuo. The residue was triturated with diethyl ether and the resulting solid was collected by filtration then dissolved in water, basified with saturated aqueous sodium hydrogen carbonate solution and extracted with dichloromethane. The combined organic extracts were dried over sodium sulphate and evaporated in vacuo to give a brown oil (0.80 g, 75%) which was shown by ^H-NMR spectroscopy to consist of a mixture of the two title compounds. This mixture was used directly in the preparation of Examples 3A and 3B without further purification.
PLC 525 fSPC 7681) Preparation 4 3-Chloro-l-(3-methoxyphenethyl)piperidine hydrochloride OCH„ .HCl A solution of l-(3-methoxyphenethyl)-3-piperidinol hydrochloride (2.72 g) (see Preparation 10) and thionyl chloride t t » (3 ml) in chloroform (50 ml) was heated under reflux for 1.5 hours then cooled and evaporated in vacuo. The residue was crystallised from 2-propanol/dichloromethane to give the title compound as a colourless solid (1.31 g, 44%), m.p. 192-196°C. Found: C,56.0; H,7.2; N,4.6; C H20C1NO.HC1.0.5 H20 requires: C,56.2; H.7.4; N,4.7%.
PLC 525 (SPC 7681) Preparation 5 (3R)-Chloro-1-(3-methoxyphenethyl)piperidine A solution of methanesulphonyl chloride (1.38 g) in dichloromethane (5 ml) was added dropwise over 5 minutes to a stirred solution of (2S)-[l-(3-methoxyphenethyl)]pyrrolidinemethanol (2.35 g) (see Preparation 9) and triethylamine (1.01 g) I I ' in dichloromethane (25 ml). The mixture was stirred at room temperature for 1.5 hours, diluted with ethyl acetate, washed twice with 10% aqueous sodium carbonate solution, dried over magnesium sulphate and evaporated in vacuo. The residue was purified by chromatography on silica gel, performing a gradient elution using 0-5% ethyl acetate/dichloromethane as the eluant.
The appropriate fractions were combined and evaporated in vacuo to give the title compound as a pale yellow oil (2.06 g, 81%) which was characterised by ^H-NMR spectroscopy.
PLC 525 (SPC 7681) 1H-NMR (CDClg) g = 7.20-7.35 (m, IH), 6.74-6.88 (m, 3H), 4.00-4.12 (m, IH) , 3.82 (s, 3H), 3.15 (d, J = 7Hz, IH) , 3.6-3.9 (m, 5H) , 2.36 (t, J = 7Hz, IH), 2.15-2.27 (m, IH), 1.5-1.9 (m, 2H) ppm.
Preparation 6 (2S)-[l-(4-Methoxyphenethyl)]pyrrolidinemethanol I A mixture of (2S)-pyrrolidinemethanol (3.0 g) , I 4-methoxyphenethyl bromide (7.0 g), sodium carbonate (3.5 g) and sodium iodide (100 mg) in acetonitrile (40 ml) was heated under reflux for 16 hours and evaporated under reduced pressure. The residue was partitioned between ethyl acetate and water and the organic layer washed with water and extracted with 2M hydrochloric acid. The acidic extract was washed with ethyl acetate, basified with solid sodium carbonate and extracted with ethyl acetate. The organic extract was dried over sodium sulphate and evaporated under reduced pressure to give the title compound as a colourless oil (4.0 g, 57%).
PLC 525 (SPC 7681) IE 9118 ' 48 ^-NMR (300 MHz, CDC1 ) 5 = 7.16 (d, 2H, J = 8Hz), 6.83 (d, 2H, J = 8Hz), 3.81 (s, 3H), 3.59 (dd, lH, J = 8 and 2Hz), 3.26-3.40 (m, 2H), 2.3-3.1 (m, 7H), 1.6-2.0 (m, 4H) ppm.
Preparations 7, 8 and 9 The following tabulated Preparations are of compounds of the general formula:- I χ 5 (CH.) -X -RJ Z m These compounds were each prepared by a similar method to that described in Preparation 6 by reacting (2S)-pyrrolidineI methanol with the appropriate alkylating agent in the presence of sodium carbonate and sodium iodide and using acetonitrile as the solvent. In each case the product was obtained as a colourless oil. The product of Preparation 9 was characterised by ^H-NMR spectroscopy.
IE 9118 I PC ra ►n r—I ¢0 c < 0K CO m o o • 0 r-l co 3C II 4-1 0 ec c •rl 4U 44 0 0 ι—I Φ Cn oo Zrf 0 cc I M X I CM pc o β o Ή 4-) L CL Φ Li CM to sz • *\ r*. r-« PC ko *0 c o pL κθ KO I κθ ra Φ L •rd cr φ Li en O & σ\ I-! PC tz rko LG ι—I C o •rl 4-) L cl Φ Li CM Φ Φ ra 3 Z~s e PC PC s-z T3 m en i—l TC o • V-Z ·» σ> i—l g ra • «t CM s^z V-Z I—1 XZ « • 1 cn τ—1 r-'- ·*> en 00 00 ι—I • II • • • « in KO en r-M 00 ·« Λ I Λ ra CM * PC Φ χ—S L • r, en · PC cc • n •H o r-l κθ r-l Ch i—l 0 • o • cr 00 © * *1 *» CO Φ * o Z—s. g g KO iu CC s-z N '—z x-z PC O en CM 00 O >st- OO 00 · & • Ό • • g «· r-l 00 pd β en CM Ο- *0 CM κθ 0 Ι CL β PC £5. 00 O 0 m o 1 00 en z-v O r-1 PC • ♦ PC Pl o r-l II cn cm o en κθ I Li CL Φ Li CM Φ Φ ra PLC 525 (SPC 7681) Preparation W This was obtained by a similar method to that described in Preparation 6 using 3-piperidinol instead of (2S)-pyrrolidinemethanol and 3-methoxyphenethyl bromide instead of 4-methoxyphenethyl bromide as the starting materials. The free base obtained upon work-up was dissolved in ether and treated with I excess ethereal hydrogen chloride. The resulting precipitate was collected by filtration and dried to give the title compound as a colourless solid (17.7 g, 66%), m.p. 140-144°C. Found: C,59.1; H,8.2; N,5.3; C^H NO2.HCl.0.75 H^O requires: C,58.9; H,8.3; N,4.9%.
PLC 525 (SPC 7681) Preparation 11 N-[l-(4-Methoxyphenethyl)-2-oxopiperidin-3-yl]diphenylsulphoximine Sodium hydride (60% dispersion in oil, 0.44 g) was added to a suspension of diphenylsulphoximine (2.28 g) in xylene (25 ml) and the mixture was heated under reflux for 15 minutes then treated I I with a solution of 3-bromo-l-(4-methoxyphenethyl)-2-piperidone (3.3 g) (see Preparation 12) in xylene (10 ml). The reaction was heated under reflux for 3 hours, cooled and diluted with ethyl acetate. The organic phase was washed with water, dried over sodium sulphate and evaporated in vacuo. The residue was purified by chromatography on silica gel performing a gradient elution using 0-1% methanol/dichloromethane as the eluant. The appropriate fractions were combined and evaporated in vacuo to give the title compound as a pale yellow oil (1.80 g, 38%).
Found: C.69.9; H,6.5; N,6.2; C„,H N 0 S requires: C.69.6; Z o Zo Z 3 H,6.3; N,6.2%.
PLC 525 (SPC 7681) IE 9118 ------- 52 Preparation 12 3-Bromo-l-(4-methoxyphenethyl)-2-piperidone OCHg Br CONH Ion exchange resin, aq.NaOH, CH2C12 J A mixture of 2,5-dibromo-N-(4-methoxyphenethyl)pentanamide (13.0 g) (see Preparation 13), Amberlite® IRA-400 (Cl) ion exchange resin (3.5 ml), dichloromethane (40 ml) and 50% aqueous sodium hydroxide solution (40 ml) was stirred at room temperature for 24 hours and filtered. The filtrate was diluted with i > dichloromethane and water and the layers separated. The organic layer was washed with water, dried over sodium sulphate and evaporated in vacuo. The residue was purified by chromatography on silica gel using dichloromethane as the eluant. The appropriate fractions were combined and evaporated in vacuo to give the title compound as a colourless oil (8.94 g, 86%). Found: C,54.7; H,6.1; N,4.7; C^4HpgBrNO2 requires: C,53.9; H,5.8; N,4.5%.
PLC 525 (SPC 7681) IE 9118 Preparation 13 2,5-Dibromo-N-(4-methoxyphenethyl)pentanamide COCI Br 2,5-Dibromopentanoyl chloride (30.6 g) (see Chem. Pharm.
Bull. Japan, 30, 1225 (1982)) was added dropwise over 10 minutes to a stirred, ice-cooled solution of 4-methoxyphenethylamine (16.8 g) and triethylamine (11.2 g) in toluene (130 ml). The 1 I mixture was stirred at room temperature for 4 hours and then evaporated in vacuo. The residue was partitioned between 5% aqueous hydrochloric acid and dichloromethane and the layers were separated. The organic layer was washed with 5% aqueous sodium bicarbonate solution and water, dried over sodium sulphate and evaporated in vacuo to give the title compound as a colourless solid (34.1 g, 79%), m.p. 84-86°C.
A portion of the product was recrystallised from ethyl acetate/hexane to give analytically pure material, m.p. 86-87°C.
Found: C,42.8; H,5.1; N,3.5; C..H1nBrN0„ requires: C,42.8; ±4 ±y z H,4.9; N,3.6%.
PLC 525 (SPC 7681) IE 9118 Preparation 14 3,4-Methylenedioxyphenethy! alcohol HO 3,4-Methylenedioxyphenylacetic acid (18.0 g) was added portionwise over 30 minutes to a stirred, ice-cooled suspension of lithium aluminium hydride (4.0 g) in ether (400 ml) and the mixture was stirred at room temperature for two hours, quenched by the cautious addition of saturated aqueous ammonium chloride solution and filtered. The organic layer was washed with 10% aqueous sodium carbonate solution, dried over magnesium sulphate J I · and evaporated in vacuo to give the title compound as a pale yellow oil (15.01 g, 90%) which was characterised by ’'H-NMR spectroscopy. 1H-NMR (CDClg) § = 6.69-6.83 (m, 3H), 5.98 (s, 2H), 3.82 (dt, J = and 6Hz, 2H), 2.81 (t, J = 7Hz, 2H), 1.44 (t, J = 6Hz, IH, exchangeable with D20) ppm.
PLC 525 (SPC 7681) IE 9118 Preparation 15 3,4-Methylenedioxyphenethyl bromide HO PBr Br .0 > A solution of phosphorus tribromide (8.1 g) in carbon tetrachloride (50 ml) was added dropwise over 30 minutes to a stirred solution of 3,4-methylenedioxyphenethyl alcohol (15.0 g) (see Preparation 14) in carbon tetrachloride (200 ml) and the mixture was heated under reflux for 3 hours, cooled, washed sequentially with water (twice), 5M aqueous sodium hydroxide solution and water, dried over magnesium sulphate and evaporated in vacuo. The residue was purified by chromatography on silica ~i gel using carbon tetrachloride as the eluant. Appropriate fractions were combined and evaporated in vacuo to give the title compound as a pale yellow oil (8.3 g, 40%), which was characterised by ^H-NMR spectroscopy. 1H-NMR (CDC13) £ = 6.80 (d, J = 8Hz, 1H), 6.75 (s, 1H), 6.71 (d, J = 8Hz, 1H), 6.00 (s, 2H), 3.56 (t, J = 7Hz, 2H), 3.13 (t, J = 7Hz, 2H) ppm.
PLC 525 (SPC 7681) ’ IE 9118 b'—----.
Preparation 16 6-(2-Hydroxyethy1)-1,4-benzodioxan This was prepared as described in Preparation 14 using (l,4-benzodioxan-6-yl)acetic acid instead of 3,4-methylenedioxyphenylacetic acid. The title compound was obtained as a colourless oil (19.8 g, 92%), which was characterised by ’'H-NMR spectroscopy.
’'H-NMR (CDCl ) £ = 6.84 (d, J = 8Hz, IH), 6.77 (d, J = 2Hz, IH) , I 3 I * 6.73 (dd, J = 8 and 2Hz, IH), 4.28 (s, 4H), 3.59 (t, J = 7Hz, 2H), 3.08 (t, J = 7Hz, 2H) ppm.
Preparation 17 6-(2-Bromoethyl)-l,4-benzodioxan HO PLC 525 (SPC 7681) IE 9-518 This was prepared as described in Preparation 15 using 6-(2-hydroxyethyl)-l,4-benzodioxan (see Preparation 16) instead of 3,4-methylenedioxyphenethyl alcohol. The title compound was obtained as a pale yellow oil (21.4 g, 80%) which was characterised by ’'H-NMR spectroscopy.
’'H-NMR (CDClg) g = 6.83 (d, J = 8Hz, IH), 6.77 (d, J = 2Hz, IH), 6.72 (dd, J = 8 and 2Hz, IH), 4.28 (s, 4H), 3.59 (t, J = 7Hz, 2H), 3.10 (t, J = 7Hz, 2H) ppm.
Preparation 18 l-Chloro-2-(N-[4-methoxyphenethyl]-N-methyl)amino-2-methyIpropane OCHg N(C2H5)g, OCHg Methanesulphonyl chloride (0.78 ml) was added to a solution of 2-[N-(4-methoxyphenethyl)-N-methyl]amino-2-methylpropan-l-ol (2.37 g) (see Preparation 19) and triethylamine (1.01 g) in dichloromethane (40 ml) and the mixture was stirred at room temperature for 2 hours then evaporated in vacuo. The residue was taken up in ethyl acetate, washed with 10% aqueous sodium PLC 525 (SPC 7681) IE 9118 carbonate solution, dried over sodium sulphate and evaporated in vacuo to give the title compound as a pale yellow oil (2.30 g, 90%) which was used directly in Example 8 without characterisation or further purification.
Preparation 19 2-[N-(4-Methoxyphenethyl)-N-methyl]amino-2-methylpropan-l-ol och HCHOjHCOOH och3 37% Aqueous formaldehyde solution (2.68 g) was added to a stirred solution of 2-(4-methoxyphenethylamino)-2-methylpropanl-ol (3.35 g) (see Preparation 20) in formic acid (3.45 g) and the mixture was heated under reflux for 2.5 hours, acidified with 2M hydrochloric acid, washed with ether, basified with solid sodium hydroxide and extracted into ethyl acetate. The organic extract was dried over sodium sulphate and evaporated in vacuo. The residue was triturated with hexane to give the title compound as a colourless solid (3.20 g, 90%), m.p. 40°C. Found: C.71.1; Η,ΙΟ.Ο; N,6.0; Clz,H23NO2 requires: C,70.8; H.9.8; N,5.9%.
PLC 525 (SPC 7681) IE 9118 A ..__ Preparation 20 2-(4-Methoxyphenethylamino)-2-methylpropan-l-ol A mixture of 2-amino-2-methylpropan-l-ol (4.46 g) , 4-methoxyphenethyl bromide (10.76 g), potassium carbonate (13.8 g) and potassium iodide (8.3 g) in acetonitrile (100 ml) was heated under reflux for 20 hours and evaporated in vacuo. The residue was I > partitioned between ethyl acetate and water and the organic layer was separated, dried over sodium sulphate evaporated in vacuo.
The residual solid was recrystallised from ethyl acetate/hexane to give the title compound (6.6 g, 60%), m.p. 114-115°C. Found: C,70.1; H.9.8; N,6.2; H N02 requires: c,69.9; H,9.5; N,6.3%.
PLC 525 (SPC 7681) Preparation 21 l-Chloro-2(S)-(N-[4-methoxyphenethyl]-N-methyl)aminopropane This was prepared as described in Preparation 18 using (2S)-(N-[4-methoxyphenethyl]-N-methyl)aminopropan-l-ol (see Preparation 22) instead of 2-[N-(4-methoxyphenethyl)-Nmethyl]amino-2-methylpropan-l-ol. The title compound was obtained as an oil which was characterised by ’H-NMR spectroscopy.
I I » ’H-NMR (CDClg) S = 7.14 (d, J = 8Hz, 2H), 6.85 (d, J = 8Hz, 2H), 4.06 (sextet, J = 7Hz, IH), 3.80 (s, 3H), 2.50-2.85 (m, 6H), 2.39 (s, 3H), 1.48 (d, J = 7Hz, 3H) ppm.
PLC 525 (SPC 7681) Preparation 22 (2S)-[N-(4-Methoxyphenethyl)-N-methy1]aminopropan-l-ol aq. CH3COOH k solution of (2S)-[N-(4-methoxyphenethyl)-N-methyl]amino1-triphenylmethoxypropane (1.6 g) (see Preparation 23) in 80% aqueous acetic acid (20 ml) was heated under reflux for 3 hours, cooled and evaporated in vacuo. The residue was taken up in dichloromethane and extracted three times with 2M hydrochloric I I » acid. The combined acidic extracts were basified with 2M aqueous sodium hydroxide solution and extracted with dichloromethane, The organic extract was washed three times with water, dried over sodium sulphate and evaporated in vacuo. The residue was purified by chromatography on silica gel performing a gradient elution using 1-2% 0.880 aqueous ammonia/ethyl acetate as the eluant. The appropriate fractions were combined and evaporated in vacuo to give the title compound (0.25 g) as an oil. Found: C,68.6; H,9.4; N,6.4; ε13Η21Νθ2.0.25 H20 requires: C,68.6; H,9.5; N,6.2%.
PLC 525 (SPC 7681) «fc. > Preparation 23 (2S)-[N-(4-Methoxyphenethyl)-Ν-methyl]amino-l-triphenylmethoxypropane H 37% Aqueous formaldehyde solution (0.6 ml) was added to a solution of (2S)-(4-methoxyphenethylamino)-l-triphenylmethoxypropane (450 mg) (see Preparation 24) in methanol (10 ml) and the mixture stirred at room temperature for 5 minutes, treated with I sodium cyanoborohydride (400 mg) and stirred at room temperature for 21 hours. The reaction was basified with 15% aqueous sodium hydroxide solution and evaporated in vacuo. The residue was partitioned between ethyl acetate and water and the organic layer separated, dried over magnesium sulphate and evaporated iri vacuo.
The residue was purified by chromatography on silica gel performing a gradient elution using 0-2% methanol/dichloromethane as the eluant. The appropriate fractions were combined and evaporated in vacuo to give the title compound as a colourless oil (321 mg, 69%). Found: C,80.8; H,7.5; N,2.8; C^H^NOg.0.5 H20 requires: C,81.0; H,7.7; N,3.0%.
PLC 525 (SPC 7681) Preparation 24 (2S)-(4-Methoxyphenethylamino)-l-triphenylmethoxypropane Na2CO3,NaI,CH3CN A mixture of (2S)-amino-l-triphenylmethoxypropane (13.16 g) (see Preparation 25), 4-methoxyphenethyl bromide (8.60 g), sodium carbonate (20.0 g) and sodium iodide (1.0 g) in acetonitrile (100 ml) was heated under reflux for 40 hours, allowed to cool to room temperature and diluted with ethyl acetate and water. The layers i were separated and the organic layer was washed with water, dried over sodium sulphate and evaporated in vacuo. The residue was purified by chromatography on silica gel performing a gradient elution using 0-3% saturated methanolic ammonia/dichloromethane as the eluant. The appropriate fractions were combined and evaporated in vacuo to give the desired product (7.9 g, 44%) as a colourless oil. Found: C,82.0; H,7.3; N,2.9; requires: C,82.5; H,7.6; N,3.1%.
PLC 525 (SPC 7681) Preparation 25 (2S)-Amino-l-triphenylmethoxypropane HO n_?2 (C6H5)3CC1 C°CH„ Ξ 3 NH.
Triphenylmethyl chloride (5.6 g) and (2S)-aminopropan-l-ol (1.5 g) were mixed to a paste and heated at 140°C for 25 minutes. The resulting hot syrup was poured into dichloromethane and the solution evaporated in vacuo. The residue was purified by chromatography on silica gel performing a gradient elution using t I » 0-4% methanol/dichloromethane plus 0.1% 0.880 aqueous ammonia as the eluant. The appropriate fractions were combined and evaporated in vacuo to give the title compound (5.13 g), m.p. 176°C. Found: C,83.2; H,7.2; N,4.4; y NO requires: C.83.3; H,7.3; N,4.4%.
PLC 525 (SPC 7681) Preparation 26 Diphenylsulphoximine 1) NCNH .Acetone, £>K02cch3)2 2) aq. KMnO4 (a) (W2 II S=N-CN (b) aq. H2SO4 V (C^^NH (a) N-Cyanodiphenylsulphoximine A mixture of diphenylsulphide (18.3 g, 0.1 mol) and cyanamide (4.62 g, 0.11 mol) in acetone (100 ml) was treated with iodobenzene diacetate (35.4 g, 0.11 mol) portionwise over 5 I I » minutes with shaking and the resulting mixture was stirred for 15 minutes at room temperature. The reaction was diluted with acetone (40 ml) and water (60 ml) then treated cautiously with potassium permanganate (19.0 g, 0.12 mol) portionwise with stirring over 5 minutes. The mixture was stirred at room temperature for 15 minutes, diluted with water, evaporated in vacuo to half-volume, treated with sodium hydrogen sulphite and extracted with chloroform. The combined organic extracts were filtered and the filtrate evaporated in vacuo. The residue was crystallised from ether to give N-cyanodiphenylsulphoximine (17.6 g, 72%) as colourless crystals, m.p. 113-116°C. Found: C,64.3; H.4.1; N,11.6; C^H^OS requires: C.64.4; H,4.2; N,11.6%. ί t * * PLC 525 (SPC 7681) (b) Diphenylsulphoximine A solution of the product of part (a) (15 g, 62 mmol) in water (30 ml) and concentrated sulphuric acid (30 ml) was heated under reflux for 1.5 hours. The reaction was allowed to cool to room temperature, poured cautiously into a mixture of concentrated aqueous ammonia solution (80 ml) and ice (80 g) and the mixture extracted with ethyl acetate. The combined organic extracts were washed with water then brine, dried over potassium carbonate and evaporated in vacuo. The residue was recrystallised from aqueous methanol to give the title compound (9.2 g, 68%) as colourless crystals, m.p. 99-102°C. Found: C,66.2; H,5.0; N,6.7; C^H-^NOS requires: C,66.5; H,5.1; N,6.45%.
’ PLC 525 (SPC 7681) IE 9118

Claims (18)

1. A compound having the formula:- (I) or a pharmaceutically acceptable salt thereof, wherein R and r’’ are each independently H or C^-C^ alkyl; X is a group of the formula:--CH, I , ' or and C _N —(CH„) -X 1 -R 5 I I 2 m 1 3 1 4 R R A PLC 525 (SPC 7681) IE 9118 wherein 2. 3 either R is H or C^-C^ alkyl and R is C^-C^ alkyl, or 2 3 R and R taken together represent -(CHg)^.- wherein r is an integer of from 2 to 5; R is C^-C^ alkyl; χΐ is a direct link, 0 or S; R 3 is a group of the formula:- either either R 8 and R 7 are each independently H, halo, C^-C^ a Ikyl, C.-C, alkoxy, -(CH.) OH, -(CH.) NR 8 R 9 , -CONR 1 °R 11 , 14 Z S Z S -SO 2 NH 2 or -000(0^-0^ alkyl), or R 6 and R 7 taken ' 2 3 together represent a group of the formula -X -(CH^ -X 2 3 wherein X and X are each independently 0 or CH 2 and t is an integer of from 1 to 3; 8 9 8 R and R are each independently H or C^-C^ alkyl, or R is hydrogen and R 9 is -SO 2 (C^-C 4 alkyl), -CONr’Or’’’, -CO(C.J-C 4 alkyl) or -SO 2 NH 2 ; R^O and r’’ are each independently hydrogen or C^-C^ alkyl; Het is thienyl, pyridinyl or pyrazinyl; m is 1, 2 or 3; n is 0, 1 or 2; p is 0 or 1; and PLC 525 (SPC 7681) s is 0, 1 or 2: with the provisos that (a) when m is 1, is a direct link and R 3 is as defined above except for Het; and (b) when n is zero, the N-substituted pyrrolidinyl or piperidinyl ring is not attached via it’s 2-position to the adjacent sulphoximine nitrogen atom.
2. A compound according to claim 1 wherein R and R^ are both H
3. A compound according to claim 1 or claim 2 wherein X is a group of the formula:R 2 ' 1 5 -CH„ — C -N — (CH„) — X —R 2 l 3 k R R 2 3 and R is H or methyl and R is methyl.
4. A compound according to claim 3 wherein R is methyl. I
5. A compound according to claim 1 or claim 2 wherein X is a group of the formula:-
6. A compound according to claim 5 wherein n is 0 or 1.
7. A compound according to any one of claims 1 to 6 wherein X^ is a direct link. c
8. A compound according to any one of claims 1 to 7 wherein R“ is 3- or 4-methoxyphenyl, 4-hydroxyphenyl, 3,4-methylenedioxyphenyl or 1,4-benzodioxan-6-yl. PLC 525 (SPC 7681)
9. The compound (3R)-N-[l-(4-methoxyphenethyl)piperidin-3-yl]diphenylsulphoximine or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising a compound of the formula (I) as claimed in any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.
11. A compound of the formula (I) as claimed in any of claims 1 to 9 or a pharmaceutically acceptable salt or composition thereof for use as a medicament, particularly for use in humans for the treatment of irritable bowel syndrome.
12. The use of compounds of the formula (I), as claimed in claim 1 or a pharmaceutically acceptable salt or composition thereof, for the manufacture of a medicament for the treatment of diseases associated with motility disorders of the gut including irritable bowel syndrome, and for the treatment of emesis, diverticular I disease and urinary incontinence.
13. A compound of the formula (I) given and defined in claim 1 or a pharmaceutically acceptable salt thereof, which is any one of those specifically hereinbefore mentioned, other than a compound as claimed in claim 9.
14. A process for the preparation of a compound of the formula (I) given and defined in claim 1 or a pharmaceutically acceptable salt thereof, substantially as hereinbefore described with particular reference to the accompanying Examples and Preparations.
15. A compound of the formula (I) given and defined in claim 1 or a pharmaceutically acceptable salt thereof, whenever prepared by a process claimed in claim 14.
16. A pharmaceutical composition according to claim 10, substantially as hereinbefore described.
17. Use according to claim 11, substantially as hereinbefore described.
18. Use according to claim 12, substantially as hereinbefore described.
IE001891A 1990-01-06 1991-01-04 Diphenylsulphoximine muscarinic receptor antagonists IE910018A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909000303A GB9000303D0 (en) 1990-01-06 1990-01-06 Therapeutic agents

Publications (1)

Publication Number Publication Date
IE910018A1 true IE910018A1 (en) 1991-07-17

Family

ID=10668924

Family Applications (1)

Application Number Title Priority Date Filing Date
IE001891A IE910018A1 (en) 1990-01-06 1991-01-04 Diphenylsulphoximine muscarinic receptor antagonists

Country Status (8)

Country Link
EP (1) EP0509005A1 (en)
JP (1) JPH05503094A (en)
CA (1) CA2072127A1 (en)
FI (1) FI922763A0 (en)
GB (1) GB9000303D0 (en)
IE (1) IE910018A1 (en)
PT (1) PT96418A (en)
WO (1) WO1991010648A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1168700A (en) * 1966-12-22 1969-10-29 Warner Lambert Pharmaceutical N-Substituted Aminoalkyl-S, S-Diphenyl-Sulfoximines and Process for Their Production.
DE1568734C3 (en) * 1966-12-22 1974-03-28 Goedecke Ag, 1000 Berlin N-dialkyl-aminoalkyl-S-diphenylsulfoximines and their salts and processes for their preparation
DE2539220A1 (en) * 1975-09-03 1977-03-17 Heumann Ludwig & Co Gmbh SUBSTITUTED SULFOXIMIDES, THE METHOD FOR MANUFACTURING THEIR PRODUCTS AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE2920958C2 (en) * 1979-05-23 1981-06-11 Ludwig Heumann & Co GmbH, 8500 Nürnberg Process for the preparation of S, S-diarylsulfoximide derivatives
CA1102803A (en) * 1980-02-04 1981-06-09 Manfred Haake Process for the production of substituted sulphoximides

Also Published As

Publication number Publication date
CA2072127A1 (en) 1991-07-07
WO1991010648A1 (en) 1991-07-25
JPH05503094A (en) 1993-05-27
EP0509005A1 (en) 1992-10-21
GB9000303D0 (en) 1990-03-07
PT96418A (en) 1991-10-15
FI922763A0 (en) 1992-06-15

Similar Documents

Publication Publication Date Title
CA2067817C (en) Muscarinic receptor antagonists
CA2012295C (en) Pyrrolidine derivatives
EP0505376B1 (en) Muscarinic receptor antagonists
EP0505377B1 (en) Muscarinic receptor antagonists
WO1992005172A2 (en) Muscarinic receptor antagonists
EP0510003B1 (en) Piperidine and pyrrolidine derivatives
EP0350309B1 (en) Piperidine derivatives
EP0508988B1 (en) Muscarinic receptor antagonists
CA1338416C (en) Muscarinic receptor antagonists
EP0441852B1 (en) Muscarinic receptor antagonists
US5486527A (en) Anticholinergic agents
US5932594A (en) Muscarinic receptor antagonists
IE910018A1 (en) Diphenylsulphoximine muscarinic receptor antagonists
IE910021A1 (en) Disubstituted piperidines and pyrrolidines as anticholinergic agents
US5231104A (en) 1-arylethyl-3-substituted piperidines
EP0365093A1 (en) Muscarinic receptor antagonists
IE910017A1 (en) Muscarinic receptor antagonists